ECSP024388A - Inhibidores de proteasas - Google Patents
Inhibidores de proteasasInfo
- Publication number
- ECSP024388A ECSP024388A EC2002004388A ECSP024388A ECSP024388A EC SP024388 A ECSP024388 A EC SP024388A EC 2002004388 A EC2002004388 A EC 2002004388A EC SP024388 A ECSP024388 A EC SP024388A EC SP024388 A ECSP024388 A EC SP024388A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- provides
- proteases
- cathepsin
- diseases
- Prior art date
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 239000004365 Protease Substances 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 3
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 3
- 102000035195 Peptidases Human genes 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 3
- 108090000625 Cathepsin K Proteins 0.000 abstract 2
- 102000004171 Cathepsin K Human genes 0.000 abstract 2
- 102000005600 Cathepsins Human genes 0.000 abstract 2
- 108010084457 Cathepsins Proteins 0.000 abstract 2
- 108090000526 Papain Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 235000019834 papain Nutrition 0.000 abstract 2
- 229940055729 papain Drugs 0.000 abstract 2
- 206010065687 Bone loss Diseases 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000024693 gingival disease Diseases 0.000 abstract 1
- 208000007565 gingivitis Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 235000019419 proteases Nutrition 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000003001 serine protease inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Un objetivo de la presente invención es proveer inhibidores de proteasa 4-amino-azepan-3-ona carbonil, particularmente los inhibidores de cisteína y serina proteasas, aún más particularmente los compuestos que inhiben las cisteína proteasas de la superfamilia de la papaína, todavía más particularmente los compuestos que inhiben las cisteina proteasas de la familia catepsina, más particularmente los compuestos que inhiben catepsina K y que son útiles para el tratamiento de enfermedades que pueden ser terapéuticamente modificadas por alteración de estas proteasas. De acuerdo con estos, en el primer aspecto, esta invención provee un compuesto según la Fórmula I, En otro aspecto, esta invención provee una composición farmacéutica formada de un compuesto de acuerdo a la Fórmula I y un transportador farmacéuticamente aceptable, diluyente o excipiente. Aún más, en otro aspecto esta invención provee intermediarios útiles en la preparación de los compuestos de la Fórmula I. En todavía otro aspecto, esta invención provee un método para tratar enfermedades en las que la patología de la enfermedad puede ser terapéuticamente modificada por inhibidores de proteasas de la superfamilia de la papaína, todavía más particularmente cisteína proteasas de la familia catepsina, y más particularmente catepsina K . En un sentido particular, los compuestos de esta invención son especialmente útiles para el tratamiento de enfermedades caracterizadas por pérdida ósea, tales como osteoporosis y enfermedades gingivales, tales como gingivitis y periodontitis, o por excesiva degradación del cartílago o la matriz , tales como osteoartritis y artritis reumatoidea.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59384500A | 2000-06-14 | 2000-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP024388A true ECSP024388A (es) | 2003-02-06 |
Family
ID=24376433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2002004388A ECSP024388A (es) | 2000-06-14 | 2002-12-12 | Inhibidores de proteasas |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1307204A4 (es) |
| JP (1) | JP2004503502A (es) |
| KR (1) | KR20030008220A (es) |
| CN (1) | CN1444481A (es) |
| AP (1) | AP2002002671A0 (es) |
| AR (1) | AR032622A1 (es) |
| AU (1) | AU2001268407A1 (es) |
| BG (1) | BG107327A (es) |
| BR (1) | BR0111693A (es) |
| CA (1) | CA2412353A1 (es) |
| CZ (1) | CZ20024086A3 (es) |
| EA (1) | EA200300018A1 (es) |
| EC (1) | ECSP024388A (es) |
| HU (1) | HUP0301231A2 (es) |
| IL (1) | IL153421A0 (es) |
| MA (1) | MA25758A1 (es) |
| MX (1) | MXPA02012442A (es) |
| NO (1) | NO20025786L (es) |
| NZ (1) | NZ522965A (es) |
| OA (1) | OA12288A (es) |
| PE (1) | PE20011374A1 (es) |
| PL (1) | PL360508A1 (es) |
| SK (1) | SK17592002A3 (es) |
| WO (1) | WO2001095911A1 (es) |
| ZA (1) | ZA200209808B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034159A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| KR20040004445A (ko) * | 2000-11-22 | 2004-01-13 | 스미스클라인 비참 코포레이션 | 프로테아제 억제제 |
| NZ526883A (en) | 2001-02-20 | 2005-11-25 | Chugai Pharmaceutical Co Ltd | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| US7709510B2 (en) | 2001-02-20 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
| EP1401453A4 (en) * | 2001-05-17 | 2005-04-06 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| GB0220187D0 (en) * | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| WO2005037258A2 (en) | 2003-08-01 | 2005-04-28 | Chugai Seiyaku Kabushiki Kaisha | Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors |
| JP4648317B2 (ja) | 2003-08-01 | 2011-03-09 | 中外製薬株式会社 | マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なピペリジン化合物 |
| ATE487475T1 (de) | 2003-08-01 | 2010-11-15 | Chugai Pharmaceutical Co Ltd | Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer |
| JP5587790B2 (ja) | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | 化合物 |
| CN103275070A (zh) * | 2013-05-10 | 2013-09-04 | 郑彪 | 调节单核细胞增殖的四环化合物及其应用 |
| US9427441B2 (en) | 2014-02-19 | 2016-08-30 | Indiana University Research And Technology Corporation | Targeting primary cilia to treat glaucoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2285A1 (fr) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| BR9916488A (pt) * | 1998-12-23 | 2001-10-09 | Smithkline Beecham Corp | Inibidores de protease |
| WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| EP1235577A4 (en) * | 1999-11-10 | 2003-04-09 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| WO2002017924A1 (en) * | 2000-09-01 | 2002-03-07 | Smithkline Beecham Corporation | Method of treatment |
| KR20040004445A (ko) * | 2000-11-22 | 2004-01-13 | 스미스클라인 비참 코포레이션 | 프로테아제 억제제 |
| EP1401453A4 (en) * | 2001-05-17 | 2005-04-06 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
-
2001
- 2001-06-14 HU HU0301231A patent/HUP0301231A2/hu unknown
- 2001-06-14 EP EP01946344A patent/EP1307204A4/en not_active Withdrawn
- 2001-06-14 SK SK1759-2002A patent/SK17592002A3/sk not_active Application Discontinuation
- 2001-06-14 CZ CZ20024086A patent/CZ20024086A3/cs unknown
- 2001-06-14 CN CN01813500A patent/CN1444481A/zh active Pending
- 2001-06-14 WO PCT/US2001/019062 patent/WO2001095911A1/en not_active Ceased
- 2001-06-14 KR KR1020027017045A patent/KR20030008220A/ko not_active Withdrawn
- 2001-06-14 NZ NZ522965A patent/NZ522965A/en unknown
- 2001-06-14 AR ARP010102840A patent/AR032622A1/es not_active Application Discontinuation
- 2001-06-14 PL PL36050801A patent/PL360508A1/xx not_active Application Discontinuation
- 2001-06-14 AP APAP/P/2002/002671A patent/AP2002002671A0/en unknown
- 2001-06-14 JP JP2002510089A patent/JP2004503502A/ja active Pending
- 2001-06-14 OA OA1200200377A patent/OA12288A/en unknown
- 2001-06-14 CA CA002412353A patent/CA2412353A1/en not_active Abandoned
- 2001-06-14 PE PE2001000566A patent/PE20011374A1/es not_active Application Discontinuation
- 2001-06-14 BR BR0111693-2A patent/BR0111693A/pt not_active IP Right Cessation
- 2001-06-14 IL IL15342101A patent/IL153421A0/xx unknown
- 2001-06-14 EA EA200300018A patent/EA200300018A1/ru unknown
- 2001-06-14 MX MXPA02012442A patent/MXPA02012442A/es unknown
- 2001-06-14 AU AU2001268407A patent/AU2001268407A1/en not_active Abandoned
-
2002
- 2002-11-28 BG BG107327A patent/BG107327A/bg unknown
- 2002-12-02 NO NO20025786A patent/NO20025786L/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209808A patent/ZA200209808B/en unknown
- 2002-12-12 EC EC2002004388A patent/ECSP024388A/es unknown
- 2002-12-13 MA MA26952A patent/MA25758A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ522965A (en) | 2004-06-25 |
| NO20025786D0 (no) | 2002-12-02 |
| EP1307204A4 (en) | 2004-06-02 |
| CA2412353A1 (en) | 2001-12-20 |
| OA12288A (en) | 2003-12-12 |
| WO2001095911A1 (en) | 2001-12-20 |
| BR0111693A (pt) | 2004-04-06 |
| KR20030008220A (ko) | 2003-01-24 |
| EA200300018A1 (ru) | 2003-06-26 |
| CZ20024086A3 (cs) | 2003-05-14 |
| MA25758A1 (fr) | 2003-04-01 |
| SK17592002A3 (sk) | 2003-05-02 |
| BG107327A (bg) | 2003-07-31 |
| AU2001268407A1 (en) | 2001-12-24 |
| CN1444481A (zh) | 2003-09-24 |
| JP2004503502A (ja) | 2004-02-05 |
| ZA200209808B (en) | 2004-07-09 |
| IL153421A0 (en) | 2003-07-06 |
| AP2002002671A0 (en) | 2002-12-31 |
| EP1307204A1 (en) | 2003-05-07 |
| MXPA02012442A (es) | 2003-04-25 |
| PE20011374A1 (es) | 2002-04-07 |
| PL360508A1 (en) | 2004-09-06 |
| HUP0301231A2 (hu) | 2003-08-28 |
| AR032622A1 (es) | 2003-11-19 |
| NO20025786L (no) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20024528D0 (no) | Proteaseinhibitorer | |
| GT200400076A (es) | Ligandos de receptores de cannabinoides y sus usos | |
| PA8601001A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| NO20044207L (no) | Katepsin som cysteinproteaseinbibitorer | |
| EP1372655A4 (en) | CATHEPSINCYSTEIN PROTEASE INHIBITORS | |
| NO20013124D0 (no) | Protease inhibitorer | |
| ECSP044998A (es) | Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina | |
| DOP2004000888A (es) | 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes | |
| PY0202788A (es) | Inhibidores de la metaloproteinasa de la matriz | |
| BR0210644A (pt) | Composto, formulação farmacêutica, método para inibir uma protease que cliva pós prolina/alanina, método para o tratamento ou profilaxia de distúrbios, e, uso do composto | |
| TR200002940T2 (tr) | Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi | |
| DE60231207D1 (de) | Inhibitoren | |
| MXPA02012442A (es) | Inhibidores de proteasa. | |
| BRPI0408417A (pt) | métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição | |
| AR123132A1 (es) | Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| UY26026A1 (es) | Inhibidores de proteasas | |
| WO2005013909A3 (en) | Novel cathepsin k inhibitors | |
| UY26088A1 (es) | Inhibidores de proteasas | |
| WO2002092563A3 (en) | Protease inhibitors | |
| WO2003053331A3 (en) | Protease inhibitors | |
| AR029855A1 (es) | Formas de sal de un inhibidor de la proteasa del hiv | |
| ECSP992905A (es) | Compuestos y composiciones farmaceuticas para el tratamiento de la malaria | |
| PA8601101A1 (es) | 2-hidroxi-3-diaminoalcanos de benzamida | |
| DE10390702D2 (de) | 2-Methylthiazolidin-2,4-Dicarbonsäure und deren Salze zur Behandlung von neurodegenerativen Erkrankungen | |
| TH51676A (th) | สารยับยั้งโพรทิเอส |